Search Results - Hawthorne, Thomas

Chemical inhibition of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) by GSK2830371 potentiates the sensitivity to MDM2 inhibitors in a p53-dependent manner by Esfandiari, Arman, Hawthorne, Thomas A., Nakjang, Sirintra, Lunec, John

Get full text Get full text Get full text

Initial Testing (Stage 1) of Glembatumumab Vedotin (CDX-011) by the Pediatric Preclinical Testing Program by Kolb, E. Anders, Gorlick, Richard, Billups, Catherine A., Hawthorne, Thomas, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.

Get full text Get full text Get full text

Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma by McGregor, Bradley A., Gordon, Michael, Flippot, Ronan, Agarwal, Neeraj, George, Saby, Quinn, David I., Rogalski, Mark, Hawthorne, Thomas, Keler, Tibor, Choueiri, Toni K.

Get full text Get full text Get full text

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma by Duvvuri, Umamaheswar, George, Jonathan, Kim, Seungwon, Alvarado, Diego, Neumeister, Veronique, Chenna, Ahmed, Gedrich, Richard, Hawthorne, Thomas, LaVallee, Theresa, Grandis, Jennifer R., Bauman, Julie E.

Get full text Get full text Get full text

Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies by Ansell, Stephen M., Flinn, Ian, Taylor, Matthew H., Sikic, Branimir I., Brody, Joshua, Nemunaitis, John, Feldman, Andrew, Hawthorne, Thomas R., Rawls, Tracey, Keler, Tibor, Yellin, Michael J.

Get full text Get full text Get full text

MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB by Rose, April A. N., Annis, Matthew G., Frederick, Dennie T., Biondini, Marco, Dong, Zhifeng, Kwong, Lawrence, Chin, Lynda, Keler, Tibor, Hawthorne, Thomas, Watson, Ian R., Flaherty, Keith T., Siegel, Peter M.

Get full text Get full text Get full text

Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent by Marquez-Nostra, Bernadette V., Lee, Supum, Laforest, Richard, Vitale, Laura, Nie, Xingyu, Hyrc, Krzysztof, Keler, Tibor, Hawthorne, Thomas, Hoog, Jeremy, Li, Shunqiang, Dehdashti, Farrokh, Ma, Cynthia X., Lapi, Suzanne E.

Get full text Get full text Get full text

Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma by Ott, Patrick A., Hamid, Omid, Pavlick, Anna C., Kluger, Harriet, Kim, Kevin B., Boasberg, Peter D., Simantov, Ronit, Crowley, Elizabeth, Green, Jennifer A., Hawthorne, Thomas, Davis, Thomas A., Sznol, Mario, Hwu, Patrick

Get full text Get full text Get full text

IT-30 ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA by Reardon, David, Schuster, James, Tran, David, Fink, Karen, Nabors, Louis, Li, Gordon, Lukas, Rimas, Desjardins, Annick, Ashby, Lynn, Duic, J. Paul, Aneiro, Lynn, Hawthorne, Thomas, Green, Jennifer, Yellin, Michael, Davis, Thomas, Sampson, John

Get full text Get full text

Phase 2 Trial of the GPNMB-Targeted Antibody-Drug Conjugate, Glembatumumab Vedotin (CDX-011) in Recurrent Osteosarcoma AOST1521: A Report from the Children’s Oncology Group (COG) by Kopp, Lisa M., Malempati, Suman, Krailo, Mark, Gao, Yun, Buxton, Allen, Weigel, Brenda J., Hawthorne, Thomas, Crowley, Elizabeth, Moscow, Jeffrey A., Reid, Joel M., Villalobos, Victor, Randall, R. Lor, Gorlick, Richard, Janeway, Katherine A.

Get full text Get full text Get full text

Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers by Anandasabapathy, Niroshana, Breton, Gaëlle, Hurley, Arlene, Caskey, Marina, Trumpfheller, Christine, Sarma, Popi, Pring, James, Pack, Maggi, Buckley, Noreen, Matei, Irina, Lyden, David, Green, Jennifer, Hawthorne, Thomas, Marsh, Henry C., Yellin, Michael, Davis, Thomas, Keler, Tibor, Schlesinger, Sarah J.

Get full text Get full text Get full text

Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study by Vahdat, Linda T., Schmid, Peter, Forero-Torres, Andres, Blackwell, Kimberly, Telli, Melinda L., Melisko, Michelle, Möbus, Volker, Cortes, Javier, Montero, Alberto J., Ma, Cynthia, Nanda, Rita, Wright, Gail S., He, Yi, Hawthorne, Thomas, Bagley, Rebecca G., Halim, Abdel-Baset, Turner, Christopher D., Yardley, Denise A.

Get full text Get full text Get full text

3BNC117 a Broadly Neutralizing Antibody Suppresses Viremia in HIV-1-Infected Humans by Caskey, Marina, Klein, Florian, Lorenzi, Julio C. C., Seaman, Michael S., West, Anthony P., Buckley, Noreen, Kremer, Gisela, Nogueira, Lilian, Braunschweig, Malte, Scheid, Johannes F., Horwitz, Joshua A., Shimeliovich, Irina, Ben Avraham-Shulman, Sivan, Witmer-Pack, Maggi, Platten, Martin, Lehmann, Clara, Burke, Leah A., Hawthorne, Thomas, Gorelick, Robert J., Walker, Bruce D., Keler, Tibor, Gulick, Roy M., Fätkenheuer, Gerd, Schlesinger, Sarah J., Nussenzweig, Michel C.

Get full text Get full text Get full text

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption by Scheid, Johannes F., Horwitz, Joshua A., Bar-On, Yotam, Kreider, Edward F., Lu, Ching-Lan, Lorenzi, Julio C. C., Feldmann, Anna, Braunschweig, Malte, Nogueira, Lilian, Oliveira, Thiago, Shimeliovich, Irina, Patel, Roshni, Burke, Leah, Cohen, Yehuda Z., Hadrigan, Sonya, Settler, Allison, Witmer-Pack, Maggi, West, Anthony P., Juelg, Boris, Keler, Tibor, Hawthorne, Thomas, Zingman, Barry, Gulick, Roy M., Pfeifer, Nico, Learn, Gerald H., Seaman, Michael S., Bjorkman, Pamela J., Klein, Florian, Schlesinger, Sarah J., Walker, Bruce D., Hahn, Beatrice H., Nussenzweig, Michel C., Caskey, Marina

Get full text Get full text Get full text